Fas-670A>G polymorphism is not associated with an increased risk of acute myeloid leukemia development

Abstract

The association between the increased risk of acute myeloid leukemia (AML) and Fas promoter polymorphisms has been reported previously; however, the results are inconclusive. The present study performed one case-control study to investigate the association, and a total of 98 AML patients and 2,014 healthy controls were genotyped. The data showed that the distribution of Fas-670AA, GA and GG genotypes among the AML patients were not significantly different from those of the healthy controls, all P>0.05. Following this a sub-study was conducted to analyze individuals who neither smoked nor drank. The results demonstrated that there was still no significant association between the Fas-670 polymorphism and risk of AML development, all P>0.05. Furthermore, in order to address a more accurate estimation of the association, a meta-analysis was conducted. Data were systematically collected from the Pubmed, EMBASE and the Wanfang Library. A total of 3 studies were included in this meta-analysis, which contained 1,144 AML cases and 3,806 controls. No significant association was detected between the Fas-670A>G polymorphism and AML risk [GA+GG vs. AA: odds ratio (OR) 0.93; 95% confidence interval (CI), 0.79–1.09; GG vs. AA: OR, 1.01; 95% CI, 0.82–1.24; GA vs. AA: OR, 1.12; 95% CI, 0.94–1.32; GG vs. AA+GA: OR, 0.94; 95% CI, 0.79–1.12; G vs. A: OR, 1.01; 95% CI, 0.91–1.12; all P>0.05). The analysis clearly indicated that there was no significant connection between the Fas-670A>G polymorphism and the increased risk of AML.

Apoptosis in megakaryocytes: Safeguard and threat for thrombopoiesis

“…DR2 is a type I transmembrane protein that belongs to the TNF receptor family, while FasL is a type II transmembrane protein belonging to the TNF superfamily ( 79 ). The DR2 receptor binds to its cognate ligand FasL and recruits DR2-associated death domain protein (FADD) and caspases 8/10 through its intracellular death domain to form a death-inducing signaling complex, which in turn activates other procaspases, ultimately leading to apoptosis ( 80 , 81 ).…”

ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies

“…Interestingly, this malignancy may also develop in healthy FAS-mutated relatives of ALPS patients [8]. In a wider perspective, a relationship between cancer risk and FAS polymorphisms is controversial [23,[86][87][88]. A meta-analysis argues for a reduction of cancer risk in individuals bearing FAS-1377 G/A SNP [86].…”

“…A meta-analysis argues for a reduction of cancer risk in individuals bearing FAS-1377 G/A SNP [86]. Similarly, a previous hypothetical association between FAS-670 A/G SNP and acute myeloid leukemia (AML) has been rejected [88]. On the other hand, SNPs in codons FAS-1377 and FASL-844 correlated with bladder cancer [81] and neuroblastoma [23].…”

CD markers polymorphisms as prognostic biomarkers in hematological malignancies

“…For example, no correlation has been reported between CD95/CD178 SNPs and AML incidence in Korean and Chinese populations. 19 , 20 In fact, it is inferred that CD95/CD178 may have different functions in various populations depending on the inherited allele. Furthermore, SNPs could modulate protective or resistance mechanisms of AML blast cells against apoptosis by altering the function of downstream genes of CD95/CD178 promoter.…”